Tag: medical marijuana

Kansas Republicans Reject Amendment To Grant Terminally Ill Patients The Right To Try Medical Marijuana

A Senate Democrat unsuccessfully attempted to insert “medicinal cannabis” among treatments allowed under a bill meant to broaden Kansans’ access to experimental drugs.

Democratic Sen. Cindy Holscher, who introduced Wednesday the amendment that would have legalized medicinal cannabis for terminally ill patients, later emphasized her intention was not to create a public medical marijuana program.

“I think most of you realize I would not bring something of that magnitude to an important bill like SB 250,” said Holscher, of Overland Park, Wednesday evening. “That amendment, rather, was to mirror what was approved by President Trump in the Right to Try Act, which is a very defined, narrow scope only for terminally ill patients.”

Senate Bill 250, introduced and carried on the Senate floor by Eudora Republican Sen. Beverly Gossage, would create the Right to Try for Individualized Investigative Treatments Act. Investigational treatments can also be referred to as experimental drugs, according to the U.S. Food and Drug Administration.

The bill would permit people who are unable to find relief from rare, life-threatening or debilitating conditions to access individualized, genetics-based medical treatment. The drug trial evaluation system in the U.S. is designed to evaluate medications meant to help larger populations, leaving behind drugs that can be individually tailored to a patient’s unique genetic makeup, Gossage said.

“Individualized treatments are being pioneered in the U.S. and abroad, but often patients in the U.S. travel thousands of miles,” she said.

The bill passed the Senate and is awaiting approval in the House.

Holscher supported the bill as a whole but voiced concerns.

“I don’t want to give people false hope,” she said, “yet I certainly would not stand in the way of a parent or individual trying to get medical help for a family member.”

Her amendment added medicinal cannabis to the list of treatments allowed under the definition of individualized investigative treatment.

Cannabis “has been found to have proven benefits for those with life-threatening or debilitating diseases,” Holscher said.

Keep reading

Florida Bill Would Let People With Opioid Use Disorder Qualify For Medical Marijuana

A newly introduced bill in the Florida Senate would expand eligibility for the state’s medical marijuana program by adding as a qualifying condition “an addiction to or dependence on an opioid drug.”

The legislation, SB 778, was filed Monday by Sen. Carlos Guillermo Smith (D). If enacted, it would take effect on July 1 of this year.

Current qualifying conditions for medical marijuana in Florida include cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn’s disease, Parkinson’s disease, multiple sclerosis, terminal conditions and chronic pain caused by a qualifying condition, according regulators at the state’s Office of Medical Marijuana Use (OMMU).

The new bill has not yet been referred to a committee, according to the state Senate website.

Smith has in the past also filed legislation to legalize cannabis for adults, and last year he criticized Gov. Ron DeSantis (R) for spending the state’s opioid settlement funds on advertisements opposing Amendment 3, an industry-funded ballot measure that would have legalized adult-use cannabis in the state.

“Thousands of Floridians have died from opioid overdoses. ZERO Floridians have died from marijuana overdose,” he said on social media last October. “Yet DeSantis is spending MILLIONS of Florida’s opioid settlement money meant to fight the opioid crisis on his prohibitionist anti-freedom, anti-marijuana campaign.”

Keep reading

GOP Florida Lawmaker Wonders If State’s Medical Marijuana Program Is ‘Causing More Harm Than Good’

With nearly 900,000 registered patients, Florida has the largest medical marijuana program in the country. While campaigning against a proposed constitutional amendment that would have legalized recreational cannabis last year, Gov. Ron DeSantis (R) hailed the medical program, boasting that he had legalized smokeable weed in the state in 2019.

But that doesn’t mean the Florida GOP-controlled legislature is all in with medical marijuana, and on Tuesday one House member asked a state doctor charged with analyzing the effectiveness of cannabis as medicine if its use by Floridians poses more of a risk than a benefit.

“You’ve made it very clear that there needs to be more research across the gamut of this area, but you’ve also made it clear that a lot of the research that you do have shows this program to be of questionable medical value,” said Northeast Florida Republican Dean Black to Dr. Almut Winterstein, a professor in the College of Pharmacy at the University of Florida and director of the Consortium for Medical Marijuana Outcomes Research.

“My question is, do you fear that we’re causing more harm than good?”

Winterstein replied that the question illuminated the “conundrum” that exists when it comes to the medical efficacy of cannabis, which because it is listed as a Schedule I controlled substance by the federal government has always had restrictions placed on research. (The Biden administration proposed last year to reclassify the substance as a Schedule III controlled substance).

“That is concerning,” she said in response to Black’s query. “That doesn’t mean that there are not patients who might massively benefit from this, but we haven’t defined the benefit of this.”

In her presentation to the House Professions & Programs Subcommittee, Winterstein reported rapid growth among young adults up to age 25 in Florida in listing anxiety as the medical condition motivating them to seek a medical marijuana prescription. She said that was “fairly strong evidence that marijuana attacks the developing brain negatively—specifically, cognitively.”

But she said that was very different than looking at patients suffering from chronic pain or other medical conditions. 

Keep reading

Arkansas Senate Passes Bill To Use Medical Marijuana Revenue To Fund Free Breakfasts For Students

The Arkansas Senate has approved a bill to set aside revenue from medical marijuana taxes to pay for free breakfast for students.

The legislation, SB 59, would supplement federal free and reduced-price meal funds with money from a state Food Insecurity Fund, paid for by cannabis taxes as well as private grants and money from the state’s general fund.

Bill sponsor Sen. Jonathan Dismang (R), noted ahead of the floor vote that “25 percent of our kids wake up food insecure every single day when they go to school.”

“Sometimes that meal that they get at school is the only nutritious meal they get in a day,” he said. “These kids have no way to feed themselves, and if they have parents that aren’t willing to sign the cards or send them with money, those districts are required to feed them, and they build up debt. But this would allow every kid in the state of Arkansas to be entitled to have a free breakfast.”

The legislation would provide meals to students regardless of whether or not they qualify for free or reduced-cost food under federal law.

“We would ask the first of federal dollars that are available be utilized, and anything else that’s remaining,” Dismang said. “The state of Arkansas would pick up utilizing the medical marijuana dollars to help make that district whole for providing that breakfast.”

The measure passed by a vote of 26-2 days after it was unanimously approved by the Senate Education Committee. It now heads to the House of Representatives for consideration.

The Senate’s passage of SB 59 follows an endorsement of the proposal last month from Gov. Sarah Huckabee Sanders (R), who previewed the bill in her State of the State address. Notably, Sanders, a former press secretary under the first Trump administration, has historically resisted cannabis policy reform.

“We will also use those funds to make school breakfast in Arkansas completely free for any student that chooses to participate,” she said in the speech, saying the use of medical marijuana funds would make the program “sustainable for years to come.”

Keep reading

Florida Bill Would Let Medical Marijuana Patients Grow At Home And Crack Down On Hemp-Derived Cannabinoids

A Florida lawmaker has introduced legislation that would allow medical marijuana patients in the state to grow up to two cannabis plants at home while also outlawing certain hemp-derived cannabinoids.

SB 334, sponsored by Sen. Joe Gruters (R)—who endorsed last year’s ultimately unsuccessful ballot measure that would have legalized marijuana for adults 21 and older—would require that homegrown cannabis be cultivated out of public view, “including a view from another private property,” and in an “enclosed, locked space to prevent access by unauthorized persons and persons younger than 21.”

The two-plant limit would apply to a household regardless of how many qualified patients live in the residence. Violations would be a first degree criminal misdemeanor, punishable by up to a year in jail and a $1,000 fine.

The proposal would expand the rights of medical marijuana patients in Florida while at the same time trying to rein in the state’s largely unregulated hemp-derived cannabinoid market. Specifically, it would ban from hemp products the cannabinoids delta-8 THC, delta-10 THC, tetrahydrocannabinol acetate (THCA), tetrahydrocannabivarin (THCV), tetrahydrocannabiphorol (THCP) and hexahydrocannabinol (HHC).

Delta-9 THC, meanwhile—the chief psychoactive component in marijuana—would be capped at 2 milligrams per serving and 20 mg per package. Further, the bill clarifies that a product’s delta-9 THC content would be determined through a combination of delta-9 itself and THCA, which converts into delta-9 THC when heated.

The new bill would also impose certain additional restrictions on the sale and advertising of hemp extracts, for example banning street retail stalls, sales at festivals and businesses within 500 feet of a school, day care facility or other hemp business. Public advertisements would also be generally prohibited.

Gruters, a former chair of the Florida Republican Party, was a proponent of the backed legalization measure Amendment 3 last November, appearing in an ad alongside Sen. Shevrin Jones (D) to argue that the reform would be “good for Florida” despite strong pushback from Gov. Ron DeSantis (R).

Gruters and Kim Rivers—the CEO of Trulieve, a medical marijuana company that provided the bulk of funding for Amendment 3—also met with Trump ahead of his endorsement of the constitutional amendment, as well as federal rescheduling and industry banking access.

Notably, Amendment 3 would not have legalized home cultivation of marijuana—a detail seized on by some critics of the industry-backed proposal.

Keep reading

More American Adults Use Cannabis As A Sleep Aid Than Choose Prescription Pills Or Alcohol To Fall Asleep, Poll Shows

About 16 percent of Americans aged 21 and older say they use cannabis as a sleep aid, according to a new industry-backed survey. That makes marijuana more popular for sleep than prescription sleep aids (12 percent) or alcohol (11 percent), but still not quite as common as using supplements (26 percent) or over-the-counter sleep aids (19 percent).

Overall, nearly 8 in 10 U.S. adults (79 percent) said something keeps them up at night, according to the new poll, conducted by The Harris Poll on behalf of cannabis the company Green Thumb Industries and its “incredibles” line of edibles. Fifty-eight percent, meanwhile, reported consuming at least one substance to help them sleep.

The survey included both “cannabis” and “CBD-only or CBD + melatonin products” as possible selections for participants, who could pick multiple responses. Sixteen percent said they inhale or ingest cannabis—which could refer either to marijuana or hemp products—while 10 percent said they used CBD either alone or with melatonin.

The online survey polled 2,019 U.S. adults ages 21 and older in early June 2024, and the results were released this month. It has a margin of error of ±2.5 percentage points.

Men were more likely than women to say they used cannabis (18 percent versus 15 percent, respectively) or CBD products (11 percent versus 8 percent) for sleep. Among women, people between ages 21 and 34 were most likely to use cannabis as a sleep aid, with older age groups considerably less likely. Among men, by contrast, the 35-to-44 age group was most likely to report using cannabis for sleep.

Lower-income people, with household incomes of below $50,000, were the most likely income level to report using cannabis for sleep (23 percent), with people in higher-income households reporting higher use of supplements and over-the-counter sleep aids.

Keep reading

‘I break the law to buy my child’s life-saving cannabis drug’

Until recently, Jane would have described her family as normal, law-abiding citizens. But that changed last summer, when the full-time mum started illegally buying cannabis oil online for her daughter, Annie.

The 10-year-old has a severe, rare type of epilepsy, resistant to conventional treatments.

At her worst, Annie was admitted to hospital 22 times in 22 months. Doctors warned Jane there was a very real prospect of her daughter dying from a seizure.

Jane says she doesn’t want to break the law – but the severity of Annie’s condition is such that she doesn’t care. We have changed their names to protect their identities.

“[Annie] deserves to be happy. She deserves to have this quality of life,” Jane explains. “And if I’m breaking the law by giving her this quality of life, am I wrong or is the law wrong?”

The family cannot afford a private prescription, which costs approximately £2,000 each month from one of the many clinics that have been established since the legalisation of so-called full-spectrum medical cannabis – which includes the psychoactive ingredient THC.

Keep reading

Study: Patients Less Likely To Have Suicidal Thoughts Following Medical Cannabis Use

Patients prescribed cannabis-based medicinal products (CBMPs) report decreases in the prevalence and intensity of suicidal thoughts, according to observational data published in the journal Archives of Suicide Research.

British investigators assessed rates of suicidal ideation in a cohort of patients authorized to use botanical cannabis or oil extracts. (British physicians are permitted to prescribe cannabis-based medicinal products to patients who are unresponsive to conventional medications.)

Researchers reported, “Three months after commencing treatment, there was a reduction in both the percentage of the sample reporting suicidal ideation and the mean severity of suicidal ideation. … Twelve-month follow-up indicated a substantial reduction in depressed mood with this reduction being more pronounced in those reporting SI [suicidal ideation at baseline.]”

The study’s authors concluded: “To the best of our knowledge, this is the first observational study of CBMPs to report on rates of suicidal ideation. … The current findings suggest CBMPs may be effective in reducing suicidal ideation, as well as other facets of health and well-being … while also suggesting that the presence of suicidal ideation should not be used as a reason to exclude an individual from CBMPs treatment.”

Keep reading

Federal Judge In Texas Rules That Ban On Gun Ownership By Marijuana User Is Unconstitutional As Applied

A federal judge in El Paso has ruled that the U.S. government’s ongoing ban on gun ownership by habitual marijuana users is unconstitutional in the case of a defendant who earlier pleaded guilty to the criminal charge. The court this week allowed the man to withdraw the plea and ordered that the indictment against him be dismissed.

The new ruling stops short of declaring that the law against firearm ownership by cannabis users—18 U.S.C. § 922(g)(3)—is itself unconstitutional. As applied to the defendant in the case, however, it says that government lawyers failed to demonstrate that the restriction aligns with the nation’s history of regulating gun ownership, noting that that they did “nothing in the way of proving that Defendant was intoxicated by marijuana at the time of this incident.”

David Briones, a senior U.S. District Court judge for the Western District of Texas, also acknowledged in the decision that the legal landscape around marijuana and the Second Amendment had evolved since the court first accepted the guilty plea. In the interim, the U.S. Court of Appeals for the Fifth Circuit, which includes Texas, ruled that while “some limits on a presently intoxicated person’s right to carry a weapon” may be constitutional, “disarming a sober person based on past substance usage” is not.

That case, U.S. v. Daniels, was set to be considered by the U.S. Supreme Court earlier this year but was among a number of firearms-related cases remanded back to lower courts following a separate Supreme Court decision about firearms and domestic violence.

“In the past two years alone,” Briones, a Clinton appointee, wrote in the new ruling, “the Fifth Circuit and the United States Supreme Court have heard and considered the following cases: Daniels, Rahimi, and Bruen. These cases have changed the law when it comes to the Second Amendment, and in the case of Daniels, have challenged the constitutionality of the very statute under which Defendant is charged.”

In the case, the El Paso Police Department responded to a 2021 call at the defendant’s home, entered the house and found two bags of marijuana. A search also found multiple guns inside the home. The defendant allegedly told officers that he’d used marijuana regularly for years and understood it was illegal to have both a medical marijuana card and a gun.

After the guilty plea, the defendant appealed his case to the Fifth Circuit, which later remanded it back to the district court in light of the recent precedent-setting opinions.

“This court now has a fuller picture of the Second Amendment jurisprudence as it stands today,” the order says, “and has reconsidered its position.”

Keep reading

CBD Is A ‘Promising Candidate’ For Treating Depression With ‘Few Side Effects,’ New Scientific Review Concludes

A new scientific review says there’s “accumulating” evidence that the marijuana component CBD “has antidepressant properties in humans and animals with few side effects” and may also aid in the reduction of inflammation and formation of new brain cells.

“In summary,” says the manuscript, newly accepted by the International Journal of Neuropsychopharmacology, “there is growing evidence that CBD may be a promising candidate for the treatment of depression.”

The review notes that while the anti-depressant effects of the cannabinoid have been previously reported, the mechanisms of action behind those effects are still poorly understood. “Therefore, this paper reviews the molecular targets, pharmacokinetics, and safety of CBD,” it says.

Authors from the departments of pharmacology at Nantong University, the First People’s Hospital of Yancheng and the Jiangyin Hospital of Traditional Chinese Medicine—all in Jiangsu, China—looked at recently published papers on experimental and clinical studies around CBD, concluding that effects seem to be linked to the cannabinoid’s role in reducing inflammation and enhancing neurogenesis.

As for the cannabinoids’ targets in the human body, authors wrote that “receptor mechanisms underlying CBD’s effects are very complex and involve in multiple receptors including CB1, CB2, GPR55, 5-HT1A, and PPARγ receptors.”

Keep reading